Back to search

Italy· 044317030

REPATHA*2 penne SC 140 mg 1 ml sureclick

A evolocumab product containing evolocumab, registered in Italy by AMGEN EUROPE B.V., on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC C10AX13

Checked against the register on

Informational only — not a medical device.

SOURCE REGISTER · ITPublic registernormalisedREPATHA*2 penne SC 140 mg 1 ml surecl…ATCC10AX13REGISTER NO.044317030PACKS LISTED1CHECKEDJune 4, 2026

Where it is registered

Evolocumab is registered in 15 of 19 countries.

Countries holding a registration under ATC C10AX13 (evolocumab), each read from that country’s own register.

  • This record: Italy
  • 10 of them publish a price we can compare per daily dose

Evolocumab · ATC C10AX13

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of evolocumab costs, country by country.

Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Evolocumab · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$17.24
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Active substance
Evolocumab
Manufacturer
AMGEN EUROPE B.V.
Country
Italy (IT)
ATC code
C10AX13
ATC class
Evolocumab
Defined daily dose
10 mg, P
Reimbursed
Yes
Last checked
June 4, 2026

Packs & prices · 1

1 priced
  • aic
    044317030
    REPATHA*2 penne SC 140 mg 1 ml sureclick
    EUR 647.45

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Evolocumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All evolocumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Repatha
  • Norway · Repatha

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/11611a11-901f-4996-939a-6ef2eaf6badf
GET /v1/drugs/11611a11-901f-4996-939a-6ef2eaf6badf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "price": 647.45,
  "source": "aifa",
  "currency": "EUR",
  "strength": "EVOLOCUMAB 140MG 1ML 2 UNITA' USO PARENTERALE",
  "substance": "Evolocumab",
  "equivalence_group": "DZU",
  "transparency_flag": null
}

See everything about evolocumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.